NRG1 and pancreatic ductal adenocarcinoma: Activating neuregulin 1 (NRG1) fusions, identified in approximately 0.13–0.5% of pancreatic ductal adenocarcinomas (PDACs) [76,79], represent a promising therapeutic target.